Welcome to our dedicated page for Beyond Air news (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air stock.
Beyond Air Inc (NASDAQ: XAIR) is a clinical-stage medical technology company pioneering nitric oxide delivery systems for respiratory care. This news hub provides investors and healthcare professionals with essential updates on regulatory milestones, clinical trial progress, and technological advancements related to the LungFit™ platform.
Access timely press releases covering FDA communications, partnership announcements, and research developments in pulmonary hypertension treatment. Our curated collection includes updates on international regulatory strategies and peer-reviewed study publications, offering critical insights into the company's position within the respiratory therapy market.
Key content categories include clinical trial results, device approval updates, executive leadership changes, and scientific conference presentations. This resource enables stakeholders to track the company's progress in developing NO-based solutions for ventilator-associated pneumonia and chronic lung conditions.
Bookmark this page for streamlined access to material developments affecting XAIR's market position. For comprehensive analysis of how these updates may influence investment decisions, consult your financial advisor and review official SEC filings.
Beyond Air, Inc. (NASDAQ: XAIR) announced its financial results for Q3 ended December 31, 2022, reporting a GAAP net loss of $13.8 million or ($0.43) per share, compared to $7.7 million or ($0.29) per share last year. The company is advancing the limited launch of its LungFit® PH for treating hypoxic respiratory failure, expecting initial sales in the March quarter. Research expenses rose to $5.0 million due to heightened operational costs. The firm also presented promising data on its ultra-high concentration nitric oxide therapy for solid tumors, showcasing significant survival improvements in pre-clinical studies. Cash and equivalents stand at $63.2 million.
Beyond Cancer has appointed Gavin Choy, PharmD as Chief Operating Officer, bringing over 20 years of experience in pharmaceutical and biotechnology sectors. Dr. Choy will oversee clinical trials for ultra-high concentration nitric oxide (UNO), aimed at treating solid tumors. His prior successes include leading clinical development for multiple drug applications across various countries. Beyond Cancer focuses on innovative therapies to enhance treatment options for oncology patients. The company’s UNO therapy has shown potential in preclinical studies to prevent relapse and reduce tumor metastases.
Beyond Cancer, Ltd., an affiliate of Beyond Air (NASDAQ: XAIR), has entered a sponsored research agreement with Stanford School of Medicine to advance its ultra-high concentration nitric oxide (UNO) therapy for solid tumors. Dr. Frederick M. Dirbas and Dr. Mark D. Pegram have been appointed to the Scientific Advisory Board (SAB), with Dirbas serving as Chair. This collaboration aims to influence clinical development and regulatory submissions for UNO therapy, which is being studied for its potential to enhance cancer treatment efficacy and safety. The first human study for UNO is underway, focusing on solid tumors.
Beyond Air, a medical device and biopharmaceutical company, will report its financial results for the third fiscal quarter ending December 31, 2022, on February 9, 2023. The announcement comes as the company focuses on developing inhaled nitric oxide for treating respiratory conditions and ultra-high concentration nitric oxide for solid tumors through its affiliate, Beyond Cancer. A conference call will be held at 4:30 PM ET the same day to discuss these results. Beyond Air has received FDA approval for its LungFit PH system, targeting persistent pulmonary hypertension of the newborn, and is advancing other clinical trials.
Beyond Cancer, an affiliate of Beyond Air (NASDAQ: XAIR), published pre-clinical data showing that ultra-high concentrations of nitric oxide (UNO) significantly enhance immune responses against solid tumors. The study indicated that UNO-treated mice exhibited improved survival rates and reduced tumor metastasis. These findings were detailed in the journal Cancer Cell International. The research supports the potential of UNO as an innovative treatment for solid tumors, with a first-in-human Phase 1 trial already in progress.
Beyond Air, Inc. (NASDAQ: XAIR) announced that Steve Lisi, its Chairman and CEO, will present at the Piper 34th Annual Healthcare Conference from November 29 to December 1, 2022, in New York, NY. Lisi's presentation is scheduled for November 30, 2022, from 1:10 – 1:30 PM ET. Beyond Air specializes in developing inhaled nitric oxide for respiratory conditions and ultra-high concentration nitric oxide for solid tumors. The company has FDA approval for its LungFit PH system aimed at treating persistent pulmonary hypertension in newborns.
Beyond Cancer, Ltd., a subsidiary of Beyond Air (NASDAQ: XAIR), announced promising in vivo data demonstrating that their ultra-high concentration nitric oxide (UNO) therapy combined with anti-PD-1 treatment significantly improves tumor regression rates and survival in CT26 tumor-bearing mice. This data, presented at the 37th Annual SITC Meeting in Boston, highlights the potential of UNO therapy not only to treat primary tumors but also to address metastatic disease effectively. The findings suggest a strong rationale for further advancing clinical studies in combination with immune checkpoint therapies.
Beyond Air reported its financial results for the fiscal quarter ending September 30, 2022, highlighting a net loss of $12.8 million, or ($0.40) per share. This marks an increase in loss compared to $8.7 million, or ($0.36) per share, in the same quarter last year. R&D expenses rose to $4.5 million, up from $2.8 million, driven by spending on ultra-high concentration nitric oxide (UNO). Despite a total cash burn of $10.4 million, the company has $72.5 million in cash and securities. Beyond Air is advancing its LungFit PH commercial launch and plans further studies in various respiratory conditions.
Beyond Air, Inc. (NASDAQ: XAIR) announced positive results from its LungFit PRO pilot study for treating Viral Community-Acquired Pneumonia (VCAP) with inhaled nitric oxide (NO). The study demonstrated a statistically significant reduction in the duration of oxygen support for patients treated with 150 ppm NO compared to standard supportive treatment. Safety data indicated no treatment-related adverse events. These findings support the efficacy and safety of high-concentration NO in pneumonia treatment, particularly for COVID-19 patients, and highlight Beyond Air's commitment to advancing this therapy.
Beyond Air (NASDAQ: XAIR) will report its second fiscal quarter financial results for the period ending September 30, 2022, on November 8, 2022, at 4:30 PM ET. The company focuses on developing inhaled nitric oxide for respiratory conditions and has received FDA approval for its LungFit PH system. This conference call will provide insights into the company’s financial performance and future developments.
FAQ
What is the current stock price of Beyond Air (XAIR)?
What is the market cap of Beyond Air (XAIR)?
